-- 周五盘前，医疗保健类股普遍上涨，其中道富医疗保健精选行业SPDR ETF (XLV)上涨0.3%，iShares生物科技ETF (IBB)上涨0.2%。 诺和诺德 (NVO) 股价上涨超过2%，此前该公司宣布已将其用于治疗2型糖尿病的口服索马鲁肽药物（原名Rybelsus）更名为Ozempic。
Related Articles
Australia
Barclays Adjusts Price Target on Amphenol to $180 From $175
Amphenol (APH) has an average rating of overweight and mean price target of $182.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $143.78, Change: $-3.49, Percent Change: -2.37%
$APH
Australia
Piper Sandler Adjusts Arthur J. Gallagher Price Target to $211 From $226
Arthur J. Gallagher & Co (AJG) has an average rating of overweight and mean price target of $272.42, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $214.33, Change: $+7.93, Percent Change: +3.84%
$AJG
Australia
Goldman Sachs Adjusts Price Target on Molson Coors Beverage to $50 From $48
Molson Coors Beverage (TAP) has an average rating of hold and mean price target of $46.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $42.37, Change: $-0.38, Percent Change: -0.88%
$TAP